<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancer - Prostate on VitaminDWiki</title>
    <link>http://localhost:1313/categories/cancer---prostate/</link>
    <description>Recent content in Cancer - Prostate on VitaminDWiki</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 24 Mar 2024 00:00:00 +0000</lastBuildDate>
    <atom:link href="http://localhost:1313/categories/cancer---prostate/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>50,000 IU of Vitamin D weekly greatly decreased bone loss from prostate cancer therapy - RCT</title>
      <link>http://localhost:1313/posts/50000-iu-of-vitamin-d-weekly-greatly-decreased-bone-loss-from-prostate-cancer-therapy-rct/</link>
      <pubDate>Sun, 24 Mar 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/posts/50000-iu-of-vitamin-d-weekly-greatly-decreased-bone-loss-from-prostate-cancer-therapy-rct/</guid>
      <description>&lt;!-- {maketoc Title=&#34;&#34;} --&gt;&#xA;&lt;hr&gt;&#xA;&lt;h4 id=&#34;high-dose-vitamin-d-to-attenuate-bone-loss-in-patients-with-prostate-cancer-on-androgen-deprivation-therapy-a-phase-2-rct&#34;&gt;High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT&lt;/h4&gt;&#xA;&lt;p&gt;Cancer . 2024 Mar 23. &lt;a href=&#34;https://doi.org/10.1002/cncr.35275&#34;&gt;doi: 10.1002/cncr.35275&lt;/a&gt; PDF is behind a paywall&lt;/p&gt;&#xA;&lt;p&gt;Luke J Peppone 1 2, Amber S Kleckner 3, Chunkit Fung 4, J Edward Puzas 2, Jennifer E Reschke 1, Eva Culakova 1, Julia Inglis 5, Charles Kamen 1, Jonathan W Friedberg 4, Michelle Janelsins 1, Karen Mustian 1, Charles E Heckler 1, Supriya Mohile 4&lt;/p&gt;</description>
    </item>
    <item>
      <title>Two types of Prostate Cancer – one is far more lethal</title>
      <link>http://localhost:1313/posts/two-types-of-prostate-cancer-one-is-far-more-lethal/</link>
      <pubDate>Thu, 14 Mar 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/posts/two-types-of-prostate-cancer-one-is-far-more-lethal/</guid>
      <description>&lt;p&gt;&lt;img src=&#34;http://localhost:1313/attachments/d3.mock.jpg&#34; alt=&#34;image&#34; width=&#34;350&#34;&gt; &lt;img src=&#34;http://localhost:1313/attachments/d3.mock.jpg&#34; alt=&#34;image&#34; width=&#34;350&#34;&gt;&lt;/p&gt;&#xA;&lt;!-- {maketoc Title=&#34;&#34;} --&gt;&#xA;&lt;hr&gt;&#xA;&lt;h4 id=&#34;genomic-evolution-shapes-prostate-cancer-disease-type&#34;&gt;Genomic evolution shapes prostate cancer disease type&lt;/h4&gt;&#xA;&lt;p&gt;Cell Geonomics VOL 4, # 3, 100511, MARCH 13, 2024 &lt;a href=&#34;https://doi.org/10.1016/j.xgen.2024.100511&#34;&gt;https://doi.org/10.1016/j.xgen.2024.100511&lt;/a&gt;&lt;/p&gt;&#xA;&lt;p&gt;Dan J. Woodcock, Atef Sahli, Ruxandra Teslo, Rosalind A. Eeles 43, Colin S. Cooper 43, David C. Wedge 43, 46&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Highlights&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&#xA;&lt;p&gt;Analysis of genomic data from localized prostate cancer reveals divergent evolution&lt;/p&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;p&gt;The shift away from the canonical trajectory is characterized by AR dysregulation&lt;/p&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&#xA;&lt;p&gt;Tumors can be classified into evotypes according to evolutionary trajectory&lt;/p&gt;</description>
    </item>
    <item>
      <title>1.5X more likely to die of Prostate Cancer if low vitamin D when initially diagnosed – meta-analysis</title>
      <link>http://localhost:1313/posts/15x-more-likely-to-die-of-prostate-cancer-if-low-vitamin-d-when-initially-diagnosed-meta-analysis/</link>
      <pubDate>Wed, 13 Mar 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/posts/15x-more-likely-to-die-of-prostate-cancer-if-low-vitamin-d-when-initially-diagnosed-meta-analysis/</guid>
      <description>&lt;!-- {maketoc Title=&#34;&#34;} --&gt;&#xA;&lt;hr&gt;&#xA;&lt;h4 id=&#34;association-between-pretreatment-blood-25-hydroxyvitamin-d-level-and-survival-outcomes-in-patients-with-clinically-localized-prostate-cancer-an-updated-meta-analysis&#34;&gt;Association Between Pretreatment Blood 25-Hydroxyvitamin D Level and Survival Outcomes in Patients With Clinically Localized Prostate Cancer: An Updated Meta-Analysis&lt;/h4&gt;&#xA;&lt;p&gt;Nutr Cancer. 2024 Mar 13:1-9. &lt;a href=&#34;https://doi.org/10.1080/01635581.2024.2328378&#34;&gt;doi: 10.1080/01635581.2024.2328378&lt;/a&gt; PDF is behind $53 paywall&lt;/p&gt;&#xA;&lt;p&gt;Feilun Cui 1 2, Yue Qiu 3, Wei Xu 3, Chen Zou 4, Yu Fan 3&lt;/p&gt;&#xA;&lt;p&gt;Studies on the prognostic value of the blood 25-hydroxyvitamin D level have yielded controversial results in prostate cancer (PCa) patients. This updated meta-analysis aimed to evaluate the association between pretreatment 25-hydroxyvitamin D level with survival outcomes among patients with clinically localized PCa. PubMed, Web of Science, and Embase databases were searched to identify studies evaluating the association of pretreatment 25-hydroxyvitamin D level with PCSM and all-cause mortality among clinically localized PCa patients. Ten cohort studies with 10,394 patients were identified. The meta-analysis revealed that PCa patients with the lowest 25-hydroxyvitamin D levels had an increased risk of PCSM (adjusted hazard ratio &lt;span&gt;[HR]&lt;/span&gt;  &lt;strong&gt;1.52&lt;/strong&gt; ; 95% confidence interval &lt;span&gt;[CI]&lt;/span&gt; 1.26-1.83; p &amp;lt; 0.001) and all-cause mortality (adjusted HR 1.31; 95% CI 1.00-1.90; p = 0.047) compared to those with higher reference 25-hydroxyvitamin D level. Subgroup analyses based on different sample sizes, follow-up duration, and adjusted times of blood draw also exhibited a significant association of vitamin D deficiency with the risk of PCSM. Lower pretreatment level of 25-hydroxyvitamin D may be an independent predictor of reduced survival in patients with clinically localized PCa. Measuring the pretreatment blood 25-hydroxyvitamin D level can provide valuable information for risk stratification of survival outcomes in these patients.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Prostate Cancer - interview of Dr. Hollick by Baggerly - video and transcript</title>
      <link>http://localhost:1313/posts/prostate-cancer-interview-of-dr-hollick-by-baggerly-video-and-transcript/</link>
      <pubDate>Thu, 18 Jan 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/posts/prostate-cancer-interview-of-dr-hollick-by-baggerly-video-and-transcript/</guid>
      <description>&lt;!-- {maketoc Title=&#34;&#34;} --&gt;&#xA;&lt;hr&gt;&#xA;&lt;h4 id=&#34;diagnosis-prostate-cancer-an-interview-with-dr-michael-holick-and-carole-baggerly&#34;&gt;Diagnosis Prostate Cancer: An Interview with Dr. Michael Holick and Carole Baggerly&lt;/h4&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;a href=&#34;https://www.youtube.com/watch?v=BMjmsmtdYnM&amp;amp;ab_channel=vitaminDaction&#34;&gt;YouTube 48 minutes&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;img src=&#34;http://localhost:1313/attachments/d3.mock.jpg&#34; alt=&#34;image&#34; width=&#34;400&#34;&gt;&#xA;&lt;hr&gt;&#xA;&lt;h4 id=&#34;transcript&#34;&gt;Transcript&lt;/h4&gt;&#xA;&lt;p&gt;(Actual Start at 0:00:13)&lt;/p&gt;&#xA;&lt;p&gt;0:02:33.6  &lt;strong&gt;Carole:&lt;/strong&gt;  Welcome to one of our fantastic interviews with Dr Michael Holick. Dr. Holick today is gonna talk with us about prostate cancer and what he&amp;rsquo;s done about it. Obviously, he&amp;rsquo;s got it. So we need to know more about how he has been working with it and any advice he has for those that could benefit. So Dr. Holick, why don&amp;rsquo;t you kick it off.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
